

**General Announcement**  
Reference No **II-110301-39856**

Company Name : **INSAS BERHAD**  
Stock Name : **INSAS**  
Date Announced : **02/03/2011**

Type : **Announcement**  
Subject : **OTHERS**

Description : **INVESTMENT IN SENGENICS SDN BHD (“SENGENICS”)**

**Announcement Details/Table Section :**

The Board of Directors of Insas Berhad (“Insas”) is pleased to announce that Insas Technology Berhad (“ITB”), a wholly-owned subsidiary of Insas had on 2 March 2011 subscribed for 20,000 ordinary shares of RM1.00 each representing 20% equity interest in Sengenics for a total subscription price of RM20,000 and 2,000,000 redeemable convertible preference shares of RM0.01 each (“RCPS”) for a total subscription price of RM2,000,000 (collectively “the Subscription”).

Sengenics is a private limited company incorporated in Malaysia and its principal activity is to provide microarray products and associated services for cutting-edge genetic-based research and clinical diagnostics. Sengenics has been awarded BioNexus Status by the Malaysian Biotechnology Corporation Sdn Bhd on the 16th November 2010 to conduct commercialization of cytogenetic and molecular diagnostic products and services and to undertake related research and development activities.

Sengenics is the strategic partner of Oxford Gene Technology (Operations) Ltd (“OGT”) exclusively for fourteen countries in Asia and the Middle East.

OGT was founded in 1995 by the pioneer of Southern Blotting and microarray technologies, Professor Sir Edwin Southern. The Company is based in Oxford, UK. OGT provides innovative clinical genetics and diagnostic solutions to advance molecular medicine. The key focus areas of OGT are high-throughput microarray and biomarker discovery; cytogenetics products and services; digital microarray/single cell analysis and licensing of fundamental array patents. [www.ogt.co.uk](http://www.ogt.co.uk).

The investment in Sengenics provides an opportunity for Insas Group to have a footprint in the life sciences field, which has tremendous growth potential in Asia.

None of the Directors and substantial shareholders of Insas or persons connected to them, has any interest, direct or indirect, in the Subscription.